• How Nuclear ERK Shapes Translation in Cardiomyocytes

  2026-08-26

  Uchida and colleagues identify a compartment-specific mechanism in which nuclear ERK phosphorylates 4EBP1 at Ser64 to reposition translation toward the cardiomyocyte interior during concentric hypertrophy. The study distinguishes mTORC1 control of overall translation from ERK-dependent spatial organization, offering a framework for interpreting how kinase localization can shape cell architecture.

• PTGER4–HDAC Signaling in Rectal Epithelium

  2026-08-25

  Anbazhagan et al. identify a stromal–epithelial signaling mechanism in which mesenchymal stromal cell-derived PGE2 activates PTGER4 and alters class IIa HDAC phosphorylation in rectal organoids. The pathway increases SPINK4 mRNA and extracellular SPINK4, providing a mechanistic framework for epithelial repair and for interpreting PTGER4 activity in inflammatory bowel disease.

• From Epitope Maps to Human IgG Readouts

  2026-08-25

  How M1R/B6R antibody discovery informs translational assay design, and where a Cy3-conjugated anti-human IgG secondary antibody can strengthen the evidence chain without overstating antiviral validation.

• Nifedipine: Calcium Assay Design Beyond PXR Models

  2026-08-24

  Nifedipine (BAY-a-1040) is more than an L-type calcium channel blocker: it is a useful perturbation tool for separating calcium-dependent phenotypes from transcriptional and metabolic adaptation. This article connects rigorous calcium, viability, iron-transport, and pathogen assays with lessons from a recent PXR rat study.

• Open-Platform DLP for 96-Well Hydrogel Printing

  2026-08-24

  Mathis and colleagues introduce a low-cost, open-platform digital light printer that fabricates patterned 2D hydrogels and locally activates photocaged DNA in 96-well formats. Its LabVIEW control, planar correction, wavelength flexibility, and vessel compatibility address reproducibility and customization constraints in high-throughput biomaterials workflows.

• Acetylcysteine for Redox Assay Design

  2026-08-23

  Learn how Acetylcysteine and N-acetyl-L-cysteine can be deployed as controllable redox perturbation tools in cell, organoid, hepatic, respiratory, and neurodegeneration workflows. The article also translates a photothermal–immune nanoplatform study into practical assay controls without implying that NAC was part of the original formulation.

• Phosbind Acrylamide for Phosphorylation Analysis

  2026-08-22

  Phosbind Acrylamide enables antibody-independent visualization of phosphorylation-dependent mobility shifts directly in SDS-PAGE. This article translates the reagent into practical workflows for stress signaling, kinase assays, and plant defense research while emphasizing controls, optimization, and assay limitations.

• Dovitinib (TKI-258) Experimental Workflows

  2026-08-22

  Dovitinib (TKI-258, CHIR-258) supports mechanism-focused studies of FLT3, c-Kit, FGFR, VEGFR, and PDGFR signaling in cancer models. This guide translates its multitarget profile into practical workflows for pathway validation, apoptosis induction, library design, and troubleshooting.

• Chemistry of Silybin: Structure, Separation, and Derivatives

  2026-08-21

  Křen and colleagues provide a comprehensive chemistry-focused analysis of silybin, linking its stereochemical assignment to isolation, diastereomer separation, total synthesis, and derivative development. The review clarifies why distinguishing individual flavonolignans from the broader Silymarin mixture is essential for reproducible analytical, mechanistic, and translational research.

• β-Elemene: Mechanisms and Cell-Model Evidence

  2026-08-20

  β-Elemene, also called Levo-β-elemene, is a C15H24 sesquiterpene used in apoptosis, metabolic, inflammation, and neuroprotection research. In a 3T3-L1 adipocyte model, β-elemene reduced lipid accumulation and improved insulin-resistance-associated changes through AMPK pathway activation.

• Measuring Drug Responses in Cancer In Vitro

  2026-08-20

  Hannah R. Schwartz’s dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central contribution is a framework for separating growth inhibition from cell killing and interpreting their distinct proportions and timing, improving the design of in vitro studies and the evaluation of cancer epigenetics experiments.

• LY2603618: Chk1 Inhibitor Workflow Guide

  2026-08-19

  LY2603618 enables controlled interrogation of Chk1-dependent replication-stress survival, G2/M checkpoint signaling, and chemotherapy sensitization. This workflow connects DNA-damage readouts with the thioredoxin–ribonucleotide reductase axis to improve responder profiling in non-small cell lung cancer research.

• Azilsartan: Reframing AT1 Signaling in Neuroinflammation

  2026-08-19

  Azilsartan (TAK-536) offers translational researchers a precise way to interrogate AT1 receptor signaling across cardiovascular and neuroinflammation models. Drawing on a 2024 study of gastrodin, microglia-conditioned media, reactive astrocytes, and the RAS–SIRT3 axis, this article outlines how to use AT1 blockade to separate pathway causality from broad anti-inflammatory effects.

• Metabolic Intervention Amplifies Ferroptosis and Cuproptosis

  2026-08-18

  Zhang et al. developed a copper–tannic acid/liposome nanosystem that packages STF-31 to inhibit glycolysis and compensatory NAD+ metabolism. By reducing glucose, NAD+, NADPH, ATP, glutathione synthesis, and copper efflux, the platform co-sensitized tumors to ferroptosis and cuproptosis while also promoting immunogenic cell death and antitumor T-cell activity.

• Flubendazole: Autophagy Research Guide

  2026-08-18

  Flubendazole is a benzimidazole derivative supplied as a research-use autophagy activator. Its defined chemical identity, DMSO handling profile, and evidence boundaries support controlled autophagy modulation research without implying direct antifibrotic or clinical activity.

543 records 6/37 page Previous Next First page 上5页 678910 下5页 Last page